Sector News

Boston Scientific to buy Endo’s urology portfolio for $1.65 billion

March 2, 2015
Life sciences
(Reuters) – Medical device maker Boston Scientific Corp (BSX.N) said it will buy Endo International Plc’s (ENDP.O) American Medical Systems’ men’s and prostate health business for up to $1.65 billion.
 
The purchase ends a nearly decade-long deal drought for Boston Scientific, which has not completed a large takeover since its 2006 acquisition of heart device maker Guidant Corp for $27 billion.
 
The deal value includes additional $50 million in milestone based on 2016 sales, Boston Scientific said on Monday.
 
AMS’ men’s and prostate health businesses, which generated 2014 sales of about $400 million, provides treatments for conditions such as erectile dysfunction, enlarged prostate and bladder leakage.
 
Reuters reported last week that Boston Scientific was close to buying Endo’s AMS medical device unit.
 
Monday’s deal, which is expected to close in the third quarter of 2015, does not include AMS’ women’s health business.
 
Endo said in a separate statement it is evaluating strategic alternatives for the business.
 
Boston Scientific said it will finance the deal through a combination of existing and newly committed credit facilities.
 
BofA Merrill Lynch is Endo’s financial adviser and Skadden Arps Slate Meagher & Flom LLP the legal adviser.
 
J.P. Morgan Securities is financial adviser to Boston Scientific.
 
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D’Souza)

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach